Profil
Yves Desgagné is the founder and Chief Technology Officer & Software Engineer of 10032506 Canada, Inc. which is founded in 2016.
Postes actifs de Yves Desgagné
| Sociétés | Poste | Début |
|---|---|---|
10032506 Canada, Inc.
 10032506 Canada, Inc. Packaged SoftwareTechnology Services 10032506 Canada, Inc. is a Canadian Montreal-based company founded in 2016 by Marc Reeves, Etienne de Villers-Sidani, and Yves Desgagné. The company has developed a patented mobile technology for capturing digital biomarkers of neurodegenerative and mental diseases such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, and related disorders, frontotemporal dementia, and related disorders, as well as cancer-related cognitive disorders ("chemo brain"). The technology is embodied in an ISO/HIPAA-compliant system consisting of an intuitive iPad Pro application connected to a cloud-based artificial intelligence infrastructure. The application consists of a series of simple visual tasks that are completed in a matter of minutes, and the users' eye movements and gaze patterns are extracted and recorded in the form of hundreds of measurements called eye movement biomarkers (EMB) and gaze mapping biomarkers (GMB). The company's mission is to become the digital leader in mobile applications that can easily extract EMBs and GMBs through its AI-powered technology to better meet the needs of the healthcare system. Etienne de Villers-Sidani has been the CEO since 2016. | Fondateur | 01/01/2016 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
10032506 Canada, Inc.
10032506 Canada, Inc. Packaged SoftwareTechnology Services 10032506 Canada, Inc. is a Canadian Montreal-based company founded in 2016 by Marc Reeves, Etienne de Villers-Sidani, and Yves Desgagné. The company has developed a patented mobile technology for capturing digital biomarkers of neurodegenerative and mental diseases such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, and related disorders, frontotemporal dementia, and related disorders, as well as cancer-related cognitive disorders ("chemo brain"). The technology is embodied in an ISO/HIPAA-compliant system consisting of an intuitive iPad Pro application connected to a cloud-based artificial intelligence infrastructure. The application consists of a series of simple visual tasks that are completed in a matter of minutes, and the users' eye movements and gaze patterns are extracted and recorded in the form of hundreds of measurements called eye movement biomarkers (EMB) and gaze mapping biomarkers (GMB). The company's mission is to become the digital leader in mobile applications that can easily extract EMBs and GMBs through its AI-powered technology to better meet the needs of the healthcare system. Etienne de Villers-Sidani has been the CEO since 2016. | Technology Services |
